Inclusion Criteria:

- Male and female subjects > 18 years age

- Hepatocellular carcinoma histologically diagnosed or in case of inability to perform a
histology by non invasive radiological criteria in presence of known cirrhosis: (i)
Hepatic lesion measuring between 1 and 2 cm in diameter : CT-scan + MRI (eventually an
Ultrasound contrast) : HCC diagnosed with contrast uptake in the arterial phase and rapid
wash out in the venous /late phase on two imaging techniques.

(ii)Hepatic lesion with a diameter > 2 cm : CT-scan or MRI +alpha fetoprotein : HCC
diagnosed with contrast uptake in the arterial phase and a rapid wash out in the venous
/late phase or a alpha fetoprotein > 200µg/L

- Patient not eligible for curative treatment (transplantation, resection, destruction
or percutaneous chemo-embolization) or HCC still evolving after failure of a specific
treatment

- Score CHILD B

- ECOG performance status 0/1/2

- Score BCLC B or C

- Adequate haematologic function with haemoglobin > 8 g/dl, platelet count > 50000x
109/L, absolute neutrophil count > 1000 / mm3

- Creatinine < 2 times the upper limit of normal

- Written informed consent

Exclusion Criteria:

- Any condition that is unstable or could jeopardize the safety of the subject and
their compliance in the study

- Pregnancy

- Myocardial infarction less than 6 months, uncontrolled hypertension, congestive heart
failure(NYHA class > 2) , anti- arrhythmic treatment other than beta-blockers or
digoxin

- Digestive bleeding within 30 days before inclusion

- Hepatic transplantation

- Patients receiving or having received a statine for less than 6 months before HCC
diagnostic

- Prior use of sorafenib

- Psychiatric illness/social situations that would limit compliance with study
requirements.

- Previous or concurrent cancer, except cervical carcinoma in situ, treated basal cell
carcinoma, superficial bladder tumor. Any cancer curatively treated > 5 years prior
to entry is permitted

- Known or suspected history of allergy to sorafenib or pravastatin.